Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine

NCT00072852 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00072852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00072852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2003
Completion date
May 31, 2007
Enrollment
134 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms